Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease.
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis.
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Natalizumab induction and maintenance therapy for Crohn's disease.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Natalizumab induction and maintenance therapy for Crohn's disease.
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 Nov 03; 353(18):1912-25.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Cell Adhesion Molecules
Crohn Disease
Double-Blind Method
Female
Humans
Immunosuppressive Agents
Integrin alpha Chains
JC Virus
Leukoencephalopathy, Progressive Multifocal
Male
Natalizumab
Remission Induction
Treatment Outcome
authors with profiles
Stephen B. Hanauer